Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311198 | 0.88 | AOC3 (0.45) | SLC6A2SLC6A4AOC3IDO1TDO2 | |
| SCHEMBL11077274 | 0.88 | IDO1 (0.52) | SLC6A2SLC6A4AOC3IDO1TDO2 | |
| SCHEMBL14415573 | 0.86 | AOC3 (0.42) | SLC6A2SLC6A4AOC3IDO1TDO2 | |
| SCHEMBL7538162 | 0.86 | SLC6A2 (0.43) | SLC6A2SLC6A4AOC3IDO1TDO2 | |
| SCHEMBL9880968 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4AOC3IDO1TDO2 | |
| SCHEMBL2628025 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4AOC3IDO1TDO2 | |
| SCHEMBL19003606 | 0.81 | AOC3 (0.41) | SLC6A2SLC6A4AOC3IDO1TDO2 | |
| SCHEMBL27715706 | 0.81 | AOC3 (0.44) | AOC3IDO1TAAR1 | |
| SCHEMBL11283326 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4AOC3TAAR1 | |
| SCHEMBL3884062 | 0.80 | AOC3 (0.40) | SLC6A2SLC6A4AOC3IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885AOC3 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.